Healthcare

November 21, 2017

1

Dubai First to Launch Innovative Stem Cell Therapy for Joint Disease

Bioscience Clinic FZ LLC located in Dubai Healthcare City is pleased to launch to its latest innovative therapy for treatment of joint disease. Established since 2012, Bioscience Clinic is Dubai’s first and most advanced clinic to use stem cells taken from adipose tissue in a variety of clinical applications. Its latest therapy was first introduced in Europe by Bioscience Institute in partnership with the University of Rome, a Bioscience Clinic"...

Continue Reading >

November 20, 2017

2

E-health accelerator launched in Cape Town

E-health accelerator Digital Health Cape Town (DHCT) has opened applications for its first programme, designed to help high growth, high social impact businesses in the health space succeed.

The accelerator has been launched in response to the changing needs of healthcare providers and patients, in a bid to digitally transform the sector by assisting early-stage, innovative digital health companies.

"...

Continue Reading >

November 20, 2017

3

Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life

(AETOS Wire)-- Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families.

Taking"...

Continue Reading >

November 20, 2017

4

Prime Hospital Reiterates Commitment Enhancing Healthcare Sector with Ultrasound-Guided Nerve Blocks

Prime Hospital, one of the UAE’s leading healthcare service providers, has achieved another milestone by applying various innovative Anesthetic Techniques developed to bring pain relief to patients after surgery. This is part of the hospital’s continuous efforts to enhance its care for patients, and contribute to raising the health sector’s global competitiveness in Dubai and the UAE.

According"...

Continue Reading >

November 19, 2017

5

Emirates Hospital Reaffirms Commitment to Medical Tourism

Emirates Hospital, a leading healthcare facility owned by KBBO Group, has reaffirmed its commitment to providing medical services to tourists, particularly Chinese visitors.

During official visit and meeting with Dr. Jia Xiao Fang, President of China International Health & Medical Tourism Association (CIHMTA), China’s largest Health Tourism and Medical Tourism Industry Platform, the CEO of Emirates Healthcare Group, said Emirates Hospital"...

Continue Reading >

November 19, 2017

6

NMC Healthcare to Speak At Milken Institute London Summit on Impact of AI on Healthcare Sector

The growth operation and management (O&A) model in the healthcare sector will enable healthcare providers around the world to offer patients better services, according to the CEO of the region’s leading healthcare groups, NMC Healthcare.

Speaking ahead of his participation on a panel entitled “Transforming Healthcare with Technology” at the 2017 Milken Institute London Summit in London, Prasanth"...

Continue Reading >

November 19, 2017

7

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer

(AETOS Wire)-- AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute of Emory University, Atlanta, USA, said: “The results of the FLAURA trial may herald a shift in how we treat patients with EGFR-mutated NSCLC. The data......

Continue Reading >

November 19, 2017

8

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases

(AETOS Wire) -- AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their"...

Continue Reading >

November 15, 2017

9

Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation

(AETOS Wire)-- Macrogen Corp. (www.macrogenlab.com) announces that its Clinical Lab that provides clinical NGS services has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “Macrogen demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients,” said Bharati Jhaveri, MD, FCAP, chair of the CAP’s Council on Accreditation. “The CAP congratulates Macrogen Corp. on its recent CAP Accreditation.” The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. During the CAP accreditation......

Continue Reading >

November 15, 2017

10

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

  • Dual therapy with dabigatran consistently favourable across key sub-groups in atrial fibrillation patients following PCI with stent placement
  • Benefits shown in sub-group analyses were consistent with overall results of the trial
  • Data presented at AHA Scientific Sessions 2017 reinforce safety benefits of dabigatran

(AETOS Wire)-- Boehringer Ingelheim has shared sub-analyses from the RE-DUAL PCI™ clinical trial at the AHA Scientific Sessions"...

Continue Reading >


Forex News Headline



Forex Market Video